Noah Wald-Dickler

Noah Wald-Dickler

Auto-generated profile, based on publicly available information

Noah Wald-Dickler

Department of Medicine, Los Angeles General Medical Center , Los Angeles, California

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
NWNoah Wald-Dickler
Noah Wald-Dickler
PHPaul D. Holtom
Paul D. Holtom
MPMatthew C. Phillips
Matthew C. Phillips
RCRobert M. Centor
Robert M. Centor
RLRachael. A. Lee
Rachael. A. Lee
BSBrad Spellberg
Brad Spellberg

25 February 2021 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JKJustine J. Ko
Justine J. Ko
CWClay Wu
Clay Wu
NMNeha Mehta
Neha Mehta
NWNoah Wald-Dickler
Noah Wald-Dickler
WYWei Yang
Wei Yang
RQRenli Qiao
Renli Qiao
This study retrospectively compares the effectiveness of methylprednisolone to dexamethasone in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) requiring intensive care. This is an institutional review board approved cohort study in patients with COVID-19 requiring intensive care unit (ICU) admission. Patients admitted and requiring oxygen supplementation were treated with no steroids, methylprednisolone, or dexamethasone. This study takes place in the ICU’s at a large, tertiary, public teaching hospital serving a primarily low-income community in urban Los Angeles. All eligible patients admitted to the ICU for COVID-19 respiratory failure from March 1 to July 31, 2020 were included in this study. A total of 262 patients were grouped as receiving usual care (n = 75), methylprednisolone dosed at least at 1mg/kg/day for ≥ 3 days (n = 104), or dexamethasone dosed at least at 6 mg for ≥7 days (n = 83). All-cause mortality within 50 days of initial corticosteroid treatment as compared to usual care was calculated. The mortality effect was then stratified based on levels of respiratory support received by the patient. In this cohort of 262 patients with severe COVID-19, all-cause mortalities in the usual care, methylprednisolone, and dexamethasone groups were 41.3%, 16.4% and 26.5% at 50 days (P < 0.01) respectively. In patients requiring mechanical ventilation, mortality was 42% lower in the methylprednisolone group than in the dexamethasone group (hazard ratio 0.48, 95% CI: 0.235-0.956, P = 0.0385). In COVID-19 patients requiring mechanical ventilation, sufficiently dosed methylprednisolone can lead to a further decreased mortality as compared to dexamethasone.

7 March 2023 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
SFSarah Freling
Sarah Freling
NWNoah Wald-Dickler
Noah Wald-Dickler
JBJosh Banerjee
Josh Banerjee
CCCatherine P Canamar
Catherine P Canamar
STSoodtida Tangpraphaphorn
Soodtida Tangpraphaphorn
BSBrad Spellberg
Brad Spellberg
We sought to compare the outcomes of patients treated with intravenous (IV)-only vs. oral transitional antimicrobial therapy for infective endocarditis (IE) after implementing a new Expected Practice within The Los Angeles County Department of Health Services (LAC DHS). We conducted a multi-centered, retrospective cohort study of adults with definite or possible IE treated with IV-only vs. oral therapy at the three acute care, public hospitals in the LAC DHS system between December 2018 to June 2022. The primary outcome was clinical success at 90 days, defined as being alive, and without recurrence of bacteremia or treatment-emergent infectious complications. We identified 257 patients with IE treated with IV-only (n=211) or oral transitional (n=46) therapy who met study inclusion criteria. Study arms were similar for many demographics; however, the IV cohort was older, and had more aortic valve involvement, hemodialysis patients, and central venous catheters present. In contrast, the oral cohort had a higher percentage of IE caused by methicillin-resistant S. aureus. There was no significant difference between the groups in clinical success at 90 days or last follow-up. There was no difference in recurrence of bacteremia or readmission rates. However, patients treated with oral therapy had significantly fewer adverse events. Multivariable regression adjustments did not find significant associations between any selected variables and clinical success across treatment groups. These results demonstrate similar outcomes of real-world use of oral vs. IV-only therapy for IE, in accord with prior randomized controlled trials and meta-analyses.

1 December 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
MKMahdi Khoshchehreh
Mahdi Khoshchehreh
NWNoah Wald-Dickler
Noah Wald-Dickler
PHPaul Holtom
Paul Holtom
SBSusan M. Butler-Wu
Susan M. Butler-Wu

23 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
NWNoah Wald-Dickler
Noah Wald-Dickler
TLTodd C Lee
Todd C Lee
STSoodtida Tangpraphaphorn
Soodtida Tangpraphaphorn
SBSusan M Butler-Wu
Susan M Butler-Wu
NWNina Wang
Nina Wang
BSBrad Spellberg
Brad Spellberg
We sought to determine the comparative efficacy of fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections (cUTIs). We conducted a multicenter, retrospective cohort study involving patients with cUTI treated with outpatient oral fosfomycin vs intravenous ertapenem at 3 public hospitals in Los Angeles County between January 2018 and September 2020. The primary outcome was resolution of clinical symptoms 30 days after diagnosis. We identified 322 patients with cUTI treated with fosfomycin (n = 110) or ertapenem (n = 212) meeting study criteria. The study arms had similar demographics, although patients treated with ertapenem more frequently had pyelonephritis or bacteremia while fosfomycin-treated patients had more retained catheters, nephrolithiasis, or urinary obstruction. Most infections were due to extended-spectrum β-lactamase–producing E. coli and Klebsiella pneumoniae, 80%–90% of which were resistant to other oral options. Adjusted odds ratios for clinical success at 30 days, clinical success at last follow-up, and relapse were 1.21 (95% CI, 0.68–2.16), 0.84 (95% CI, 0.46–1.52), and 0.94 (95% CI, 0.52–1.70) for fosfomycin vs ertapenem, respectively. Patients treated with fosfomycin had significant reductions in length of hospital stay and length of antimicrobial therapy and fewer adverse events (1 vs 10). Fosfomycin outcomes were similar irrespective of duration of lead-in intravenous (IV) therapy or fosfomycin dosing interval (daily, every other day, every third day). These results would support the conduct of a randomized controlled trial to verify efficacy. In the meantime, they suggest that fosfomycin may be a reasonable stepdown from IV antibiotics for cUTI.

5 July 2022 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CVChristina Vu
Christina Vu
EKEric S Kawaguchi
Eric S Kawaguchi
CTCesar H Torres
Cesar H Torres
ALAustin H Lee
Austin H Lee
NWNoah Wald-Dickler
Noah Wald-Dickler
SKSaahir Khan
Saahir Khan
To the Editor—While preventing infection was the initial focus of the coronavirus disease 2019 (COVID-19) pandemic response, with increasing population immunity and variant transmissibility, the current focus has shifted to reducing hospitalization and deaths, particularly in vulnerable communities [ 1]. During the recent surge in disease activity driven by the Omicron variant, an increased proportion of “COVID-19 hospitalizations” were incidentally discovered infections in patients newly hospitalized for other reasons [ 2–6], resulting in decreased measurements of in-hospital disease severity and mortality compared to prior disease surges [ 6–9]. However, estimates of the proportion of total COVID-19 hospitalizations accounted for by these incidental infections range widely from 15% to 68% [ 2–6], due to heterogeneity in case definitions for these incidental infections and variability across populations with respect to vaccination status and other risk factors for severe COVID-19.